vorinostat has been researched along with Cholera Infantum in 6 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multi-institutional phase II trial assessed the activity and toxicity of a new histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic acid--SAHA) in patients with recurrent or persistent epithelial ovarian or primary peritoneal carcinoma." | 9.13 | A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( Bender, DP; Hoffman, JS; Modesitt, SC; Sill, M, 2008) |
| "The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 9.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
| "This multi-institutional phase II trial assessed the activity and toxicity of a new histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic acid--SAHA) in patients with recurrent or persistent epithelial ovarian or primary peritoneal carcinoma." | 5.13 | A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( Bender, DP; Hoffman, JS; Modesitt, SC; Sill, M, 2008) |
| "The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 5.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Holmberg, LA | 1 |
| Green, D | 1 |
| Libby, E | 1 |
| Becker, PS | 1 |
| Andersen, CL | 1 |
| McMullin, MF | 1 |
| Ejerblad, E | 1 |
| Zweegman, S | 1 |
| Harrison, C | 1 |
| Fernandes, S | 1 |
| Bareford, D | 1 |
| Knapper, S | 1 |
| Samuelsson, J | 1 |
| Löfvenberg, E | 1 |
| Linder, O | 1 |
| Andreasson, B | 1 |
| Ahlstrand, E | 1 |
| Jensen, MK | 1 |
| Bjerrum, OW | 1 |
| Vestergaard, H | 1 |
| Larsen, H | 1 |
| Klausen, TW | 1 |
| Mourits-Andersen, T | 1 |
| Hasselbalch, HC | 1 |
| Heymann, WR | 1 |
| Mendivil, AA | 1 |
| Micha, JP | 1 |
| Brown, JV | 1 |
| Rettenmaier, MA | 1 |
| Abaid, LN | 1 |
| Lopez, KL | 1 |
| Goldstein, BH | 1 |
| Duvic, M | 1 |
| Talpur, R | 1 |
| Ni, X | 1 |
| Zhang, C | 1 |
| Hazarika, P | 1 |
| Kelly, C | 1 |
| Chiao, JH | 1 |
| Reilly, JF | 1 |
| Ricker, JL | 1 |
| Richon, VM | 1 |
| Frankel, SR | 1 |
| Modesitt, SC | 1 |
| Sill, M | 1 |
| Hoffman, JS | 1 |
| Bender, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer[NCT01938833] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Closed by Sponsor) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for vorinostat and Cholera Infantum
| Article | Year |
|---|---|
Treatment of cutaneous T-cell lymphoma: focus on vorinostat.
Topics: Antineoplastic Agents; Fatigue; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; H | 2008 |
4 trials available for vorinostat and Cholera Infantum
| Article | Year |
|---|---|
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Fatigue; Female; Gastrointestinal Diseases; Hematologic | 2013 |
Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous | 2013 |
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dehydration; Disease Progression; Disease-Fre | 2007 |
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Disease-Free Survival; Female; Gas | 2008 |
1 other study available for vorinostat and Cholera Infantum
| Article | Year |
|---|---|
Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma.
Topics: Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; | 2020 |